指南与共识妇科

低级别浆液性卵巢癌2026专家共识解读

Low-grade serous ovarian cancer: 2026 expert consensus report.
指南 / 共识 · Gynecol Oncol · 2026-10-22

2026年国际多学科专家共识更新了低级别浆液性卵巢癌(LGSOC)的诊疗推荐,整合NRG-GY019等新证据,支持II-IV期术后含化疗方案为参考路径,并纳入复发病灶的靶向治疗进展与生物标志物指导策略。

要点

  • II-IV期LGSOC术后含化疗方案为新诊断参考路径,特定情况可个体化内分泌单药降阶治疗。
  • KRAS突变LGSOC复发治疗获FDA加速批准avutometinib联合defactinib。
  • 强调治疗特异性生物标志物解读、多学科协作与临床试验中心病理复核。

核心结论

  • 2026年LGSOC国际共识基于新证据更新诊疗推荐,涵盖病理、分子检测、一线与复发治疗及全程管理。

研究设计与样本

  • 国际多学科专家小组召开2026年LGSOC共识会议,审阅新证据并更新推荐。

主要发现

  • NRG-GY019数据支持含化疗的术后治疗作为II-IV期LGSOC当前参考方法。
  • 复发领域进展包括FDA加速批准avutometinib联合defactinib用于KRAS突变LGSOC,以及内分泌联合CDK4/6抑制的证据。

关键数值与推荐

  • II-IV期LGSOC术后含化疗方案为当前参考方法,特定情况可考虑内分泌单药个体化降阶。
  • KRAS突变LGSOC复发可采用avutometinib联合defactinib(FDA加速批准)。

临床怎么用

  • 按治疗特异性解读生物标志物,开展多学科协作,临床试验需中心病理复核。
  • 复发治疗可结合内分泌联合CDK4/6抑制及生物标志物指导选择。

局限性

  • 需前瞻性研究解决治疗排序、预测性生物标志物及生活质量结局等问题。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Low-grade serous ovarian carcinoma (LGSOC) is a rare epithelial malignancy characterized by frequent mitogen-activated protein kinase (MAPK) pathway alterations, hormone receptor expression, relative resistance to cytotoxic chemotherapy, and a prolonged, relapsing clinical course. Since publication of the 2023 international expert consensus, significant advances have reshaped the management of both newly diagnosed and recurrent disease. The 2026 LGSOC Consensus Conference convened an international multidisciplinary panel of experts in the field to review emerging evidence and update recommendations across pathology, molecular testing, translational biology, frontline and recurrent treatment, imaging, treatment-associated toxicity, regulatory strategy, patient advocacy, and future research priorities. Recommendations were informed by contemporary clinical evidence, multidisciplinary discussion, and patient perspectives. The updated consensus incorporates practice-changing data from NRG-GY019 supporting chemotherapy-containing postoperative therapy as the current reference approach for stage II-IV disease while recognizing selected circumstances in which endocrine monotherapy may represent individualized de-escalation. It also integrates recent advances in recurrent disease, including the US Food and Drug Administration's accelerated approval of avutometinib in combination with defactinib for KRAS-mutated LGSOC, emerging evidence supporting endocrine therapy combined with CDK4/6 inhibition, and refined guidance for biomarker-directed treatment selection, imaging assessment, toxicity management, and patient-centered survivorship. The panel emphasizes treatment-specific biomarker interpretation, multidisciplinary care, central pathology review for clinical trials, and the continued need for prospective studies addressing treatment sequencing, predictive biomarkers, and quality-of-life outcomes. This updated international consensus provides an evidence-based framework for the diagnosis and management of LGSOC while identifying priorities for future clinical research and drug development.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Grisham RN, Slomovitz B, Podder V, et al. Low-grade serous ovarian cancer: 2026 expert consensus report. Gynecol Oncol. 2026. PMID: 42913278. doi:10.1016/j.ygyno.2026.10.011

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。